With our free press under threat and federal funding for public media gone, your support matters more than ever. Help keep the LAist newsroom strong, become a monthly member or increase your support today.
FDA approves first cell therapy to treat aggressive forms of melanoma
Amtagvi is the first cell therapy for solid tumors approved by the FDA.
(
Iovance Biotherapeutics, Inc.
)
The Food and Drug Administration has approved a novel type of cancer therapy to treat aggressive forms of melanoma using immune system cells from a patient's tumor.
The treatment, called Amtagvi, was developed by Iovance Biotherapeutics, a biotech company based in San Carlos, Calif.
It is intended for patients whose melanoma cannot be removed with surgery or has spread to other parts of the body.
"The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a novel T cell immunotherapy for patients with limited treatment options," Dr. Peter Marks, the director of the FDA's Center for Biologics Evaluation and Research, said in a statement announcing the approval on Friday.
Sponsored message
Melanoma develops when the skin cells that produce pigment start to grow out of control, according to the American Cancer Society. A major risk factor is exposure to ultraviolent light, which typically comes from the sun or tanning beds.
The tumor is easy to treat when detected early. But if it's not removed in time, melanoma can quickly spread to other parts of the body.
Amtagvi is designed to fight off advanced forms of melanoma by extracting and replicating T cells derived from a patient's tumor. T cells are part of the immune system. While they can typically help fight cancer, they tend to become dysfunctional inside tumors.
The newly approved medicine is similar to CAR-T, which is mainly used to treat blood cancers. Amtagvi is the first cell therapy approved by the FDA for solid tumors.
Amtagvi was fast-tracked through the FDA's accelerated approval pathway, a program to give patients with urgent, life-threatening illnesses early access to promising treatments.
Although Amtagvi was given the greenlight, Iovance Biotherapeutics said it is in the process of conducting an additional trial to confirm the treatment's efficacy, which is required by the FDA.
Melanoma only accounts for 1% of all skin cancer cases but it has been linked to a "significant number" of cancer-related deaths, according to the FDA.
Sponsored message
The American Cancer Society estimates that in 2024, about 100,000 new cases of melanoma will be diagnosed and about 8,000 people will die from the skin cancer.
Copyright 2024 NPR. To see more, visit https://www.npr.org. 9(MDA1OTI3MjQ5MDEyODUwMTE2MzM1YzNmZA004))
At LAist, we believe in journalism without censorship and the right of a free press to speak truth to those in power. Our hard-hitting watchdog reporting on local government, climate, and the ongoing housing and homelessness crisis is trustworthy, independent and freely accessible to everyone thanks to the support of readers like you.
But the game has changed: Congress voted to eliminate funding for public media across the country. Here at LAist that means a loss of $1.7 million in our budget every year. We want to assure you that despite growing threats to free press and free speech, LAist will remain a voice you know and trust. Speaking frankly, the amount of reader support we receive will help determine how strong of a newsroom we are going forward to cover the important news in our community.
We’re asking you to stand up for independent reporting that will not be silenced. With more individuals like you supporting this public service, we can continue to provide essential coverage for Southern Californians that you can’t find anywhere else. Become a monthly member today to help sustain this mission.
Thank you for your generous support and belief in the value of independent news.
But the game has changed: Congress voted to eliminate funding for public media across the country. Here at LAist that means a loss of $1.7 million in our budget every year. We want to assure you that despite growing threats to free press and free speech, LAist will remain a voice you know and trust. Speaking frankly, the amount of reader support we receive will help determine how strong of a newsroom we are going forward to cover the important news in our community.
We’re asking you to stand up for independent reporting that will not be silenced. With more individuals like you supporting this public service, we can continue to provide essential coverage for Southern Californians that you can’t find anywhere else. Become a monthly member today to help sustain this mission.
Thank you for your generous support and belief in the value of independent news.
Senior Vice President News, Editor in Chief
